메뉴 건너뛰기
BJU International
Volumn 102, Issue 11, 2008, Pages 1491-1492
The National Institute of Health and Clinical Excellence rejects new treatments for renal cell cancer: Cinderella's invitation is cancelled
Author keywords

[No Author keywords available]
Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; INTERFERON; INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS;
EID: 56649119252     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08164.x     Document Type: Note
Times cited : (4)
References (6)
  • 1
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 356 : 115 24
    • (2007) N Engl J Med , vol.356 , pp. 115-24
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 2
    • 37349080670 scopus 로고    scopus 로고
    • Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial
    • AVOREN Trial investigators.
    • Escudier B, Pluzanska A, Koralewski P et al AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007 370 : 2103 11
    • (2007) Lancet , vol.370 , pp. 2103-11
    • Escudier, B.1    Pluzanska, A.2    Koralewski, P.3    Al, E.4
  • 3
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • Global ARCC Trail.
    • Hudes G, Carducci M, Tomczak P et al. Global ARCC Trail. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007 356 : 2271 81
    • (2007) N Engl J Med , vol.356 , pp. 2271-81
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3
  • 4
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • Target Study Group.
    • Escudier B, Eisen T, Stadler WM et al. Target Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 356 : 125 34
    • (2007) N Engl J Med , vol.356 , pp. 125-34
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 5
    • 55249103589 scopus 로고    scopus 로고
    • RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter Phase-III study
    • Suppl.): Abstract LBA5026
    • Motzer RJ, Escudier B, Oudard S et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter Phase-III study J Clin Oncol 2008 26 (Suppl.): Abstract LBA5026
    • (2008) J Clin Oncol , vol.26
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 6
    • 48649094719 scopus 로고    scopus 로고
    • Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
    • Suppl.): Abstract 5024
    • Figlin RA, Hutson TE, Tomczak P et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008 26 (Suppl.): Abstract 5024
    • (2008) J Clin Oncol , vol.26
    • Figlin, R.A.1    Hutson, T.E.2    Tomczak, P.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.